| ARGX Snapshot | |
|---|---|
| argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands. | |
| VALUATION DATA | |
| Market Capitalization | $22,203,460,000 | Price to Sales | 5.00 |
| Earnings per Share | $-5.1700 |
| PE Ratio | None |
| PRICE DATA | |
| Most Recent Close | $375.0000 |
| 52 Week High | $17.72 |
| 52 Week Low | $5.47 |
| 50-Day Moving Average | $15.71 |
| 200-Day Moving Average | $-100.18 |
| All data are from Alpha Vantage as of today. For more infomation on ARGX see Stock Dividend, Valuation, Price and Financial Data for Investors | |
Custom Search